Revance Begins Injectable Trial

Revance Therapeutics, a biopharmaceutical company, has announced Phase 2 BELMONT trial. This randomized, double-blind, dose ranging, active, and placebo controlled, multicenter study will evaluate the safety and efficacy of RT002, a botulinum toxin type A injectable intended to treat glabellar lines. The RT002 has the potential to address additional therapeutic indications where more targeted delivery is required or a longer duration is desired, for example movement disorders, urology, and ophthalmology. There are 250 participants expected to enroll at up to 10 sites in Canada. “The opportunity for a longer-lasting, more targeted neurotoxin is tremendous as it offers the potential for improved patient satisfaction and safety with longer-lasting results,” says Dan Browne, cofounder, president, and CEO of Revance Therapeutics. “Based on the current progress of our program, we expect to report top-line date from this Phase 2 study in late 2015.”

Suggested Articles

The collection launched with two new caviar-based facial moisturizers, Caviar Face Cream and Caviar Gel Face Moisturizer.

The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults and the appearance of fine lines.

Finalists will be invited to the Merz Aesthetics Expert Summit 2021, and the winner will present their work on the main stage.